Sarvarinder K. Gill

Oncology | Hematology

Philadelphia, PA 19178

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Journal: Cancers

Published: May 18, 2026

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Journal: Biomedicines

Published: July 06, 2025

B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia.

B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: June 25, 2025

Predictors of survival in gastric mucosa-associated lymphoid tissue lymphoma: An updated surveillance, epidemiology, and end results-based analysis of age and gender disparities.

Predictors of survival in gastric mucosa-associated lymphoid tissue lymphoma: An updated surveillance, epidemiology, and end results-based analysis of age and gender disparities.

Journal: World journal of clinical oncology

Published: February 26, 2025

Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies.

Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies.

Journal: World journal of gastrointestinal pharmacology and therapeutics

Published: January 23, 2025

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies.

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies.

Journal: Cancers

Published: December 24, 2024

Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.

Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.

Journal: Diseases (Basel, Switzerland)

Published: December 03, 2024

Interaction Between Age and Tumor Stage in Survival Outcomes of Patients With Mantle Cell Lymphoma.

Interaction Between Age and Tumor Stage in Survival Outcomes of Patients With Mantle Cell Lymphoma.

Journal: Journal of community hospital internal medicine perspectives

Published: November 25, 2024

Hepatic veno-occlusive disease complicated with extreme hyperammonaemia (920 µmol/L) treated with defibrotide, lactulose, rifampin and haemodialysis.

Hepatic veno-occlusive disease complicated with extreme hyperammonaemia (920 µmol/L) treated with defibrotide, lactulose, rifampin and haemodialysis.

Journal: BMJ case reports

Published: March 21, 2024

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

Journal: Leukemia & lymphoma

Published: September 23, 2023

The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.

The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.

Journal: Cancer

Published: December 05, 2022

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.

Journal: Blood cancer journal

Published: June 13, 2022

Showing 1-12 of 12

Last Updated: 09/26/2026